ID
11712
Description
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide). https://clinicaltrials.gov/ct2/show/NCT00089895
Link
https://clinicaltrials.gov/ct2/show/NCT00089895
Keywords
Versions (1)
- 7/28/15 7/28/15 -
Uploaded on
July 28, 2015
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility EARLY ACS Acute Coronary Syndrome NCT00089895
Eligibility criteria
- StudyEvent: ODM
Description
Exclusion criteria
Description
pregnancy (known or suspected)
Data type
boolean
Alias
- UMLS CUI-1
- C0549206
Description
renal dialysis within 30 days prior to randomizing in study
Data type
boolean
Alias
- UMLS CUI-1
- C0019004
Description
Stroke
Data type
boolean
Alias
- UMLS CUI-1
- C0038454
Description
central nervous system damage
Data type
boolean
Alias
- UMLS CUI-1
- C0007682
Description
bleeding disorders
Data type
boolean
Alias
- UMLS CUI-1
- C3251812
Description
major surgery
Data type
boolean
Alias
- UMLS CUI-1
- C0679637
Description
major trauma
Data type
boolean
Alias
- UMLS CUI-1
- C0332677
Description
treatment with heparin
Data type
boolean
Alias
- UMLS CUI-1
- C2825026
Description
Treatment with eptifibatide
Data type
boolean
Alias
- UMLS CUI-1
- C0253563
Similar models
Eligibility criteria
- StudyEvent: ODM